Multiplexed TCR-T Cell Compositions for Antigen Heterogeneity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing TCR-T cell therapies targeting single antigens face challenges due to heterogeneous antigen expression and HLA loss-of-heterozygosity in solid tumors, leading to incomplete responses and rapid relapse.

Innovation Solution

Multiplexed TCR-T cell therapy, which combines T cell receptors recognizing multiple antigens and HLA molecules, mimicking natural oligoclonal T cell responses to overcome antigen heterogeneity and HLA loss-of-heterozygosity, enhancing cytotoxicity through synergistic cytokine-mediated effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If single-antigen TCR-T cell therapy is used, then the therapy is simple to implement, but it fails to overcome antigen heterogeneity and HLA loss-of-heterozygosity leading to incomplete responses and rapid relapse

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidtherapy complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines multiple TCR-T cell products targeting different antigens and HLA molecules into a single multiplexed therapy. This merging approach allows simultaneous targeting of heterogeneous tumor cells expressing different antigens, overcoming the limitation of single-antigen therapies while managing complexity through integrated product design and coordinated administration

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If multiplexed TCR-T cell therapy targeting multiple antigens and HLA molecules is used, then antigen heterogeneity and HLA loss-of-heterozygosity are overcome, but the therapy complexity increases

Engineering Contradiction:

Improvetherapeutic durabilityVSAvoidproduct complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the anti-tumor response into multiple independent TCR-T cell products, each targeting a specific antigen-HLA combination. This segmentation allows each product to independently eliminate tumor cells expressing its target antigen, ensuring durable responses even when tumor cells lose one antigen or HLA molecule. The complexity is managed by producing separate, well-characterized products that can be individually optimized and tracked

Inventive Principle:

Principle #1Segmentation

3Duration of action of moving object

If single-antigen TCR-T cell therapy is administered, then the treatment protocol is simple, but complete responses are rare and responses are short-lived

Engineering Contradiction:

Improveresponse durationVSAvoidtherapy structure

Core Design Contradiction:

Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The patent creates a dynamic multi-target system where multiple TCR-T cell products continuously monitor and respond to different antigen expressions on tumor cells. As tumor cells may lose one antigen over time, the dynamic presence of multiple targeted responses ensures that anti-tumor activity is maintained through alternative targets, extending response duration without requiring complex adaptive reprogramming of the therapy

Inventive Principle:

Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The multiplexed TCR-T cell therapy achieves enhanced and sustained anti-tumor activity by independently targeting different tumor cells and boosting T cell responses via cytokine secretion, addressing the limitations of single-antigen therapies.

Implementation Method 1

discovery of certain binding proteins, including T cell receptors (TCRs), that in combination recognize more than one antigen

Methodology Applied

Scientific EffectT cell receptor-antigen binding:

Implementation Method 2

this effect was mediated via secreted soluble factors. The results demonstrate that the use of multiplexed T cell receptors and related compositions can overcome antigen heterogeneity not only through independent targeting of different target cells in the same tumor, but also by cytokine-mediated enhancement of each T cell's response

Methodology Applied

Scientific EffectCytokine-mediated enhancement: